Telix Gains FDA Approval for Pixclara in Glioma Imaging
MELBOURNE, Australia and INDIANAPOLIS, Ind. — September 14, 2026 Telix Pharmaceuticals announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MELBOURNE, Australia and INDIANAPOLIS, Ind. — September 14, 2026 Telix Pharmaceuticals announced that the U.S. Food and Drug Administration...
Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026 Telix Pharmaceuticals reported strong first-half 2026 performance, highlighting continued...
MELBOURNE, Australia; INDIANAPOLIS, Indiana; and HOUSTON, Texas, June 2, 2026 Telix Pharmaceuticals and United Imaging Healthcare North America have...
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
